NCT00353834 - The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Exenatide

Exenetide 5ug twice daily for 4 weeks, then 10ug twice daily for 8 weeks

DRUG

Glargine Insulin

Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve a fasting glucose of 100mg/dl and avoid hypoglycemia.

Trial Locations (1)

Joslin Diabetes Center, Boston